BR112012002353A2 - uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2 - Google Patents

uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2

Info

Publication number
BR112012002353A2
BR112012002353A2 BR112012002353A BR112012002353A BR112012002353A2 BR 112012002353 A2 BR112012002353 A2 BR 112012002353A2 BR 112012002353 A BR112012002353 A BR 112012002353A BR 112012002353 A BR112012002353 A BR 112012002353A BR 112012002353 A2 BR112012002353 A2 BR 112012002353A2
Authority
BR
Brazil
Prior art keywords
diabetes
type
metabolic diseases
treat cardiovascular
nkg2d
Prior art date
Application number
BR112012002353A
Other languages
English (en)
Inventor
H Raulet David
Sten Petersen Jacob
Xiong Na
Brynja Bödvarsdóttir Thóra
Mingcan Xia
Original Assignee
The Penn State Res Foudation
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Penn State Res Foudation, Univ California filed Critical The Penn State Res Foudation
Publication of BR112012002353A2 publication Critical patent/BR112012002353A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
BR112012002353A 2009-08-17 2010-08-16 uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2 BR112012002353A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23442509P 2009-08-17 2009-08-17
US30411310P 2010-02-12 2010-02-12
PCT/US2010/045627 WO2011022334A1 (en) 2009-08-17 2010-08-16 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes

Publications (1)

Publication Number Publication Date
BR112012002353A2 true BR112012002353A2 (pt) 2018-03-13

Family

ID=43014101

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002353A BR112012002353A2 (pt) 2009-08-17 2010-08-16 uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2

Country Status (11)

Country Link
US (2) US20120148581A1 (pt)
EP (1) EP2467152B1 (pt)
JP (2) JP5838158B2 (pt)
KR (1) KR20120090931A (pt)
CN (1) CN102548573B (pt)
AU (1) AU2010284428B2 (pt)
BR (1) BR112012002353A2 (pt)
CA (1) CA2769409A1 (pt)
MX (1) MX2012001999A (pt)
RU (2) RU2015138677A (pt)
WO (1) WO2011022334A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2747785A4 (en) * 2011-08-26 2015-04-15 Univ California METHOD AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES THROUGH NKG2D INHIBITION
US20140328861A1 (en) * 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
US9228006B2 (en) 2012-03-16 2016-01-05 University Health Network Methods and compositions for modulating Toso activity
US20140235552A1 (en) * 2013-02-15 2014-08-21 Claresa Levetan Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
CN105683218A (zh) * 2013-07-03 2016-06-15 大学保健网络 针对toso的抗体
US20200157541A1 (en) * 2018-11-19 2020-05-21 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2519953C (en) * 2003-03-24 2016-01-05 The Scripps Research Institute Dna vaccine against tumor growth and methods of use thereof
US7666417B2 (en) * 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
ATE435656T1 (de) * 2004-04-05 2009-07-15 Univ California Nkg2d modulation
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
PL2222706T5 (pl) * 2007-12-14 2017-09-29 Novo Nordisk As Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania

Also Published As

Publication number Publication date
CN102548573A (zh) 2012-07-04
RU2566264C2 (ru) 2015-10-20
US20150376281A1 (en) 2015-12-31
CA2769409A1 (en) 2011-02-24
EP2467152B1 (en) 2017-05-17
AU2010284428B2 (en) 2014-09-11
EP2467152A1 (en) 2012-06-27
JP2013502420A (ja) 2013-01-24
JP2016014030A (ja) 2016-01-28
JP5978362B2 (ja) 2016-08-24
MX2012001999A (es) 2012-02-29
JP5838158B2 (ja) 2015-12-24
US20120148581A1 (en) 2012-06-14
RU2015138677A (ru) 2018-12-25
CN102548573B (zh) 2016-03-16
KR20120090931A (ko) 2012-08-17
AU2010284428A1 (en) 2012-02-16
WO2011022334A1 (en) 2011-02-24
RU2012105528A (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
SMT201500140B (it) Composizione per inibire l'espressione genica e suoi usi
BRPI1014522A2 (pt) composicoes e metodos para aumentar o crescimento muscular
SMT201500280B (it) Nuove composizioni per prevenire e/o trattare disturbi da accumulo lisosomiale
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
SV2010003593A (es) Nuevos herbicidas
DK3184109T3 (da) Fremgangsmåder til forbedring af natural killer-cellers proliferation og aktivitet
ZA201008392B (en) Treatment of pluripotent cells
CR20110485A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BR112013007694A2 (pt) composição, e, métodos para aplicar uma composiçao, para aumentar a eficácia de um produto de insumo para cultura, e para induzir uma atividade de biodefesa em uma planta
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
ITTO20110627A1 (it) Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche
BRPI1008253A2 (pt) Metoso para tratar biomassa
BRPI1011912A2 (pt) l-serina para uso como medicamento para prevenir e/ou tratar uma reação inflamatória da pele.
BR112013008528A2 (pt) métodos para tratar psoríase
BR112012002353A2 (pt) uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2
EP2665793A4 (en) AZEOTROPE COMPOSITIONS OF TRANS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE AND WATER
DK3311810T3 (da) Anvendelse af sulcardin til behandling af atrieflimmer
BR112012022037A2 (pt) composição cosmética, processo de tratamento cosmético, uso de uma composição cosmética e uso de uma combinação
BRPI0907794A2 (pt) Métodos para aplicar estímulo físico às células
BR112013015048A2 (pt) composição para o tratamento de distúrbios metabólicos
DK2621517T4 (da) Sammensætning til anvendelse i behandlingen af infertilitet
EP2324709A4 (en) USE OF MENADION TO INCREASE SALT IMMERSION TOLERANCE IN PLANTS
BR112013007039A2 (pt) "composição de tratamento pessoal"
LT2536841T (lt) Silosavimo agento panaudojimas vientisos liemeninės šaknies apdorojimui
DK2566505T3 (da) Fremføring af kolesterylester til steroidogene væv

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]